blca cell line rt4 Search Results


blca cell line rt4  (Keygen Biotech)
90
Keygen Biotech blca cell line rt4
Metabolic-gene-based stratification of <t>TCGA-BLCA</t> patients. A NbClust analysis of BLCA metabolic-gene-based subtypes. B Silhouette analysis of clustering results. C UMAP visualization of metabolic subtypes in the TCGA cohort for the expression of metabolic genes. D Correlations between metabolic subtypes and clinicopathological features in BLCA. E , F Barplot showing the percentage of pathological stages ( E ) and vital status ( F ) in the MRS1 and MRS2 groups. G , H Kaplan-Meier analysis in term of OS ( G ) and PFS ( H ) in TCGA cohort
Blca Cell Line Rt4, supplied by Keygen Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/blca cell line rt4/product/Keygen Biotech
Average 90 stars, based on 1 article reviews
blca cell line rt4 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Metabolic-gene-based stratification of TCGA-BLCA patients. A NbClust analysis of BLCA metabolic-gene-based subtypes. B Silhouette analysis of clustering results. C UMAP visualization of metabolic subtypes in the TCGA cohort for the expression of metabolic genes. D Correlations between metabolic subtypes and clinicopathological features in BLCA. E , F Barplot showing the percentage of pathological stages ( E ) and vital status ( F ) in the MRS1 and MRS2 groups. G , H Kaplan-Meier analysis in term of OS ( G ) and PFS ( H ) in TCGA cohort

Journal: BMC Cancer

Article Title: A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer

doi: 10.1186/s12885-023-11182-w

Figure Lengend Snippet: Metabolic-gene-based stratification of TCGA-BLCA patients. A NbClust analysis of BLCA metabolic-gene-based subtypes. B Silhouette analysis of clustering results. C UMAP visualization of metabolic subtypes in the TCGA cohort for the expression of metabolic genes. D Correlations between metabolic subtypes and clinicopathological features in BLCA. E , F Barplot showing the percentage of pathological stages ( E ) and vital status ( F ) in the MRS1 and MRS2 groups. G , H Kaplan-Meier analysis in term of OS ( G ) and PFS ( H ) in TCGA cohort

Article Snippet: BLCA cell line RT4 (Cat. KG089) was obtained from KeyGEN (Nanjing, China).

Techniques: Expressing

Metabolic phenotypes predicted molecular subtypes and clinical therapy. A Correlations between metabolic phenotypes and molecular subtypes using seven different algorithms (CIT, Lund, MDA, TCGA, Baylor, UNC, and consensus) and BLCA signatures. B , C Mutational profiles of chemotherapy-related genes in the MRS1 and MRS2 groups in the TCGA cohort. D Comparison of oncogenic pathways associated with therapeutic-targets between the MRS1 and MRS2 groups. * p < 0.05, ** p < 0.01, *** p < 0.0001. E Left: UMAP visualization the expression distribution of PD-L1 (CD274). Right: Comparison the expression values of PD-L1 between the MRS1 and MRS2 groups. F Stacked histogram showing the percentage of MRS1 and MRS2 groups in CR/PR and PD/SD in GSE176307 cohort. CR: complete remission; PR: partial remission; PD: progression disease; SD: stable disease

Journal: BMC Cancer

Article Title: A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer

doi: 10.1186/s12885-023-11182-w

Figure Lengend Snippet: Metabolic phenotypes predicted molecular subtypes and clinical therapy. A Correlations between metabolic phenotypes and molecular subtypes using seven different algorithms (CIT, Lund, MDA, TCGA, Baylor, UNC, and consensus) and BLCA signatures. B , C Mutational profiles of chemotherapy-related genes in the MRS1 and MRS2 groups in the TCGA cohort. D Comparison of oncogenic pathways associated with therapeutic-targets between the MRS1 and MRS2 groups. * p < 0.05, ** p < 0.01, *** p < 0.0001. E Left: UMAP visualization the expression distribution of PD-L1 (CD274). Right: Comparison the expression values of PD-L1 between the MRS1 and MRS2 groups. F Stacked histogram showing the percentage of MRS1 and MRS2 groups in CR/PR and PD/SD in GSE176307 cohort. CR: complete remission; PR: partial remission; PD: progression disease; SD: stable disease

Article Snippet: BLCA cell line RT4 (Cat. KG089) was obtained from KeyGEN (Nanjing, China).

Techniques: Comparison, Biomarker Discovery, Expressing

S100A7 was up-regulated in MRS1-tumor cells. A The interactions between MRS1-tumor cells and MRS1-T cells. B The interactions between MRS1-tumor cells and MRS1-macrophages. C Comparison of metastasis characteristics between the MRS1- and MRS2-tumor cells. D Venn plot showing the shared up-regulated genes in the MRS1-tumor cells and patients with the MRS1 phenotype. For TCGA-BLCA and GSE13057 cohort, the R package “limma” was applied. Genes with adjusted P-value< 0.05 and FC ≥ 1.5 were identified the DEGs of the MRS1 group. For single cell transcriptional dataset, “FindAllMarkers” function was used to identify the specific genes of MRS1- and MRS2-tumor cells. Genes with adjusted P-value< 0.05, FC ≥ 1.5, pct.1 ≥ 0.4 & pct.2 ≤ 0.1 were identified as the DEGs of the MRS1-tumor cells. E , F Kaplan-Meier analysis in term of OS of S100A7 in the TCGA-BLCA ( E ) and the GSE13057 ( F ) cohorts. All patients were categorized into two groups based on the median of the S100A7 expression. G Correlation between S100A7 and metastatic characteristics in the scRNA-seq dataset of MRS1 and MRS2-tumor cells. H , I Correlation between S100A7 and metastatic characteristics in the TCGA-BLCA ( H ) and GSE13507 cohorts ( I )

Journal: BMC Cancer

Article Title: A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer

doi: 10.1186/s12885-023-11182-w

Figure Lengend Snippet: S100A7 was up-regulated in MRS1-tumor cells. A The interactions between MRS1-tumor cells and MRS1-T cells. B The interactions between MRS1-tumor cells and MRS1-macrophages. C Comparison of metastasis characteristics between the MRS1- and MRS2-tumor cells. D Venn plot showing the shared up-regulated genes in the MRS1-tumor cells and patients with the MRS1 phenotype. For TCGA-BLCA and GSE13057 cohort, the R package “limma” was applied. Genes with adjusted P-value< 0.05 and FC ≥ 1.5 were identified the DEGs of the MRS1 group. For single cell transcriptional dataset, “FindAllMarkers” function was used to identify the specific genes of MRS1- and MRS2-tumor cells. Genes with adjusted P-value< 0.05, FC ≥ 1.5, pct.1 ≥ 0.4 & pct.2 ≤ 0.1 were identified as the DEGs of the MRS1-tumor cells. E , F Kaplan-Meier analysis in term of OS of S100A7 in the TCGA-BLCA ( E ) and the GSE13057 ( F ) cohorts. All patients were categorized into two groups based on the median of the S100A7 expression. G Correlation between S100A7 and metastatic characteristics in the scRNA-seq dataset of MRS1 and MRS2-tumor cells. H , I Correlation between S100A7 and metastatic characteristics in the TCGA-BLCA ( H ) and GSE13507 cohorts ( I )

Article Snippet: BLCA cell line RT4 (Cat. KG089) was obtained from KeyGEN (Nanjing, China).

Techniques: Comparison, Expressing

Validation of expression and prognostic value of S100A7 in the recruited TMA cohort. A Representative images revealing S100A7 expression in tumor and paratumor tissues using anti-S100A7 staining. Magnification, 200×. B Expression levels of S100A7 in tumor and paratumor tissues. C Kaplan-Meier analysis of S100A7 in term of OS in the TMA cohort. D Association between S100A7 expression and clinicopathological features in BLCA. E Representative images revealing PD-L1 expression in the high- and low-S100A7 groups. Magnification, 200×; ( F ) Correlation between S100A7 and PD-L1 expression

Journal: BMC Cancer

Article Title: A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer

doi: 10.1186/s12885-023-11182-w

Figure Lengend Snippet: Validation of expression and prognostic value of S100A7 in the recruited TMA cohort. A Representative images revealing S100A7 expression in tumor and paratumor tissues using anti-S100A7 staining. Magnification, 200×. B Expression levels of S100A7 in tumor and paratumor tissues. C Kaplan-Meier analysis of S100A7 in term of OS in the TMA cohort. D Association between S100A7 expression and clinicopathological features in BLCA. E Representative images revealing PD-L1 expression in the high- and low-S100A7 groups. Magnification, 200×; ( F ) Correlation between S100A7 and PD-L1 expression

Article Snippet: BLCA cell line RT4 (Cat. KG089) was obtained from KeyGEN (Nanjing, China).

Techniques: Biomarker Discovery, Expressing, Staining